- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02998632
Posterior Mandibular Ridge Augmentation Using Mineralized Plasmatic Matrix Versus Autogenous Bone Graft
The Effect of Posterior Mandibular Ridge Augmentation Using Mineralized Plasmatic Matrix Versus Autogenous Bone Graft on Implant Body Stability: A Randomized Clinical Trial Comparative Study
- Patients will be diagnosed to determine whether they are eligible for the inclusion criteria of this study or not. Patients who are eligible will start their surgical treatment in the next visit after radiographic and surgical site evaluation.
- On the day of surgery, each patient will be assigned to either intervention or control group, the patients will receive inferior alveolar nerve block and long buccal nerve anesthesia. Future implant site will be planned, an incision will be made and flap will be reflected along the defective ridge.
- Implant fixture/s will be inserted in the previously planned site. Uncovered fixture threads and bone defect will be covered by MPM or autogenous bone graft.
- In the control group, autogenous particulate bone graft will be used for vertical augmentation and covered with titanium reinforced membrane. In the intervention group, MPM (Mineralized plasmatic matrix) will be used.
- Edges will be approximated, Sutures will be placed.
- Osstell instrument will be used to measure and record fixture primary stability in ISQ units.
- Patients will be referred to the fixed prosthodontics department for placement of the crowns after ensuring success of osseointegration and implant stability (after 4 months).
- Patients will evaluate their overall satisfaction after fitting the final prosthesis using a questionnaire at 9 months.
- After 9 months, CBCT will be performed to evaluate augmented bone height to be compared with the bone height previously recorded in CBCT.
- Osstell instrument will be used to evaluate the implant stability ratio in ISQ unit to be compared to the ratio recorded before.
Study Overview
Status
Conditions
Detailed Description
In the study group:
- Full medical and dental history will be obtained from all the patients participating in this study (figure 2).
- Thorough clinical and radiographic examination for the ridge area to be treated will be done.
- Future implant site will be planned.
- Each patient will be asked to evaluate their overall satisfaction using a questionnaire before any intervention.
- Patients will receive 2 gm of amoxicillin 1 hour before surgery. They will be instructed to wash their mouths with a 0.12% chlorhexidine solution for 30 seconds immediately before surgery.
- The patient will receive inferior alveolar nerve block and long buccal nerve anesthesia using articane HCl 4% with 1:100,000 adrenaline local anesthetic solution using aspirating syringe and 27-gauge needle.
- After confirming the success of profound local anaesthesia, an incision will be made and flap will be reflected along the ridge of the previously planned intraoral donor site to completely expose bone.
- Autogenous bone graft will be obtained and will be grinded according to the dimensions of the present defect.
- MPM (Mineralized plasmatic matrix) will be prepared:
Tubes of 9 ml of venous blood will be taken from the patient and will be placed in a centrifuge at 2500 rpm / min for 5 min.
At the end of the centrifugation, the blood in the tube will be separated into two compartments one yellow and one red.
The yellow part will be withdrawn with a syringe to be mixed with the grinded autogenous bone previously obtained from intra oral site.
Components will be mixed using a probe until the formation of a single homogeneous component, called the MPM (Mineralized Plasmatic Matrix).
- The graft site receiver will be prepared by perforating the lateral cortical bone to improve the vascularization and facilitate cell migration.
- Implant fixture/s will be inserted in the previously planned site.
- Uncovered fixture threads and bone defect will be covered by MPM.
- Osstell instrument will be used to measure and record fixture primary stability in ISQ units precisely and objectively 48.
- Edges will be approximated, Sutures will be placed.
- Sutures will be removed 7 days later.
- Immediate postoperative CBCT will be performed.
- Antibiotic (combination of 500mg amoxicillin and 125mg clavulanic acid) and analgesic and anti-inflammatory (Ibuprofen 600mg) will be prescribed after the surgical procedure to be administrated by the patients.
- Patients will be referred to the fixed prosthodontics department for placement of the crowns after ensuring success of osseointegration and implant stability (after 4 months).
In the control group:
- The Same previously mentioned procedure will be performed, But here gold standards are to be performed (Autogenous particulate bone graft used for vertical augmentation will be covered with titanium reinforced membrane).
- Osstell tool will be used to measure and record fixture primary stability in ISQ units.
- Suturing will be performed.
- Then Immediate Post operative CBCT will be performed.
- Antibiotic (combination of 500mg amoxicillin and 125mg clavulanic acid) and analgesic and anti-inflammatory (Ibuprofen 600mg) will be prescribed after the surgical procedure to be administrated by the patients.
- Patients will be referred to the fixed prosthodontics department for placement of the crowns after ensuring success of osseointegration and implant stability (after 4 months).
Postoperative follow up in both groups:
- After 4 months, Osstell instrument will be used to evaluate the implant stability ratio in ISQ unit to be compared to the ratio recorded before.
- After 9 months, Patients will evaluate their overall satisfaction after fitting the final prosthesis using a questionnaire to be answered by YES or NO.
- -After 9 months, CBCT will be performed to evaluate augmented bone height to be compared with the bone height previously recorded in CBCT.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Medically free patients.
- Patients with posterior mandibular defective partially edentulous ridge.
- Evaluated bone height on CBCT to be (0-4 mm buccal bone dehiscence) and width (not less than 4.5 mm)
- Patients physically able to tolerate surgical and restorative procedures.
- Patients with an opposing tooth to the pre-implant site.
- Good oral hygiene.
- Highly motivated patients.
Exclusion Criteria:
- Patients allergic to local anaesthetic agent.
- smokers.
- Pregnant or lactating females.
- Presence of any pathosis in the pre-implant site.
- Presence of parafunctional habits.
- History of oral radiotherapy.
- History of prolonged steroids use.
- Psychological disorders.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Interventional
Patients will receive 2 gm of amoxicillin 1 hour before surgery. Mouthwash 0.12% chlorhexidine solution for 30 seconds immediately before surgery. Inferior alveolar nerve block and long buccal nerve anesthesia using articane HCl 4% with 1:100,000 adrenaline local anesthetic solution. Flap will be reflected in intraoral donor site to completely expose bone. Autogenous bone graft will be obtained and will be ground. MPM (Mineralized plasmatic matrix) will be prepared. Implant fixture/s will be inserted. Uncovered fixture threads and bone defect will be covered by MPM. Osstell will be used to measure fixture primary stability in ISQ units. Sutures will be placed. Sutures will be removed 7 days later. Immediate postoperative CBCT will be performed. Antibiotic (combination of 500mg amoxicillin and 125mg clavulanic acid) and analgesic and anti-inflammatory (Ibuprofen 600mg) will be prescribed. |
Vertical bone augmentation of defective posterior mandibular alveolar ridge using MPM (Mineralized Plasmatic Matrix) bone graft.
Other Names:
|
Active Comparator: Comparator
Patients will receive 2 gm of amoxicillin 1 hour before surgery. Mouthwash 0.12% chlorhexidine solution for 30 seconds immediately before surgery. The patient will receive inferior alveolar nerve block and long buccal nerve anesthesia using articane HCl 4% with 1:100,000 adrenaline local anesthetic solution Flap will be reflected in intraoral donor site to completely expose bone. Autogenous bone graft will be obtained and will be ground. Implant fixture/s will be inserted. Uncovered fixture threads and bone defect will be covered by autogenous bone graft and covered by titanium membrane. Osstell instrument will be used to measure and record fixture primary stability in ISQ units. Sutures will be placed. Sutures will be removed 7 days later. Immediate postoperative CBCT will be performed. Antibiotic (combination of 500mg amoxicillin and 125mg clavulanic acid) and analgesic and anti-inflammatory (Ibuprofen 600mg) will be prescribed. |
Vertical bone augmentation of defective posterior mandibular alveolar ridge using autogenous bone graft (gold standard) covered by titanium membrane.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Implant body stability in ISQ unit
Time Frame: Change from baseline implant body stability at 4 months
|
Change from baseline implant body stability at 4 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Bone height in Cone beam CT
Time Frame: Change from baseline bone height at 9 months
|
Change from baseline bone height at 9 months
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Patient satisfaction using questionnare
Time Frame: 9 months
|
9 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- CEBC - CU - 2016 - 11 - 165
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bone Augmentation
-
BonusBio Group LtdRecruitingBone Augmentation | Bone GraftsIsrael
-
Ain Shams UniversityCompleted
-
Pedro TortamanoUnknownBone Augmentation | Alveolar Bone Grafting
-
Medical University of ViennaActive, not recruiting
-
The University of Texas Health Science Center at...Completed
-
Nobel BiocareUnknownHorizontal Bone AugmentationGermany, Italy, Serbia
-
Centro Specialistico Odontoiatrico, RomeRecruitingBone Augmentation | Dental Implant | Soft Tissue Augmentation | Tooth Extraction Status NosItaly
-
Botiss Medical AGCONVIDIA clinical research GmbH; botiss biomaterials GmbHRecruitingRidge Augmentation | Guided Bone Regeneration (GBR) | Periodontal Bone DefectAustria, Denmark, Italy
-
Prince Sattam Bin Abdulaziz UniversityActive, not recruitingBone Augmentation | Tooth Extraction Status NosSaudi Arabia
-
Tehran University of Medical SciencesCompletedAlveolar Ridge Augmentation | Bone Transplantation
Clinical Trials on Mineralized plasmatic matrix for bone augmentation
-
Cairo UniversityUnknown
-
Alexandria UniversityCompletedAlveolar Bone Loss | Horizontal Alveolar Bone DefectEgypt
-
Cairo UniversityUnknown
-
Cairo UniversityUnknownBone Graft; Complications
-
Cairo UniversityNot yet recruitingMaxillary Sinus Floor Elevation
-
Marmara UniversityCompleted
-
Krishnadevaraya College of Dental Sciences & HospitalUnknown
-
Mansoura UniversityActive, not recruitingDifferent Treatment Outcomes of Atrophied Distal Extension CasesEgypt
-
Austral University, ArgentinaUnknownHepatitis C | Cirrhosis | Antiviral Drug Adverse ReactionArgentina